Karyopharm Therapeutics Inc. Debt Securities, Available-for-sale, Unrealized Loss
Karyopharm Therapeutics Inc. (KPTI) reported Debt Securities, Available-for-sale, Unrealized Loss of $2.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2026-02-13
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-12-31 was -$3.00K.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-09-30 was -$121.00K.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-06-30 was -$11.00K, a 103.97% decline year-over-year.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for the quarter ending 2024-03-31 was $137.00K, a 58.98% decline year-over-year.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for fiscal 2024 was $2.00K, a 98.79% decline from fiscal 2023.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for fiscal 2023 was $165.00K, a 52.59% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for fiscal 2022 was $348.00K, a 3766.67% increase from fiscal 2021.
- Karyopharm Therapeutics Inc. debt securities, available-for-sale, unrealized loss for fiscal 2021 was $9.00K, a 80.43% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$124.00K derived: sum of 2 quarters · filed 2026-02-13 | -$135.00K derived: sum of 3 quarters · filed 2026-02-13 | $2.00K 10-K · filed 2026-02-13 |
| 2024-09-30 | -$121.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$132.00K derived: sum of 2 quarters · filed 2024-11-05 | $5.00K 10-Q · filed 2024-11-05 | -$273.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2024-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $126.00K 10-Q · filed 2024-08-06 | -$152.00K derived: sum of 3 quarters · filed 2025-02-19 | -$320.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2024-03-31 | $137.00K 10-Q · filed 2024-05-08 | -$141.00K derived: sum of 2 quarters · filed 2025-02-19 | -$309.00K derived: sum of 3 quarters · filed 2025-02-19 | -$32.00K derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-12-31 | -$278.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$446.00K derived: sum of 2 quarters · filed 2025-02-19 | -$169.00K derived: sum of 3 quarters · filed 2025-02-19 | $165.00K 10-K · filed 2025-02-19 |
| 2023-09-30 | -$168.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $109.00K derived: sum of 2 quarters · filed 2023-11-02 | $443.00K 10-Q · filed 2023-11-02 | $459.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $611.00K 10-Q · filed 2023-08-02 | $627.00K derived: sum of 3 quarters · filed 2024-02-29 | $773.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $334.00K 10-Q · filed 2023-05-04 | $350.00K derived: sum of 2 quarters · filed 2024-02-29 | $496.00K derived: sum of 3 quarters · filed 2024-02-29 | $661.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $162.00K derived: sum of 2 quarters · filed 2024-02-29 | $327.00K derived: sum of 3 quarters · filed 2024-02-29 | $348.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $146.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $311.00K derived: sum of 2 quarters · filed 2022-11-03 | $332.00K 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $165.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $186.00K 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $21.00K 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $9.00K 10-K · filed 2023-02-17 | |||
| 2020-12-31 | $46.00K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |